Pubblicazioni scientifiche

Cancella testo

Open Access

1773 pubblicazioni

Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F., The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, «CANCERS», 2020, 12, pp. 1 - 21 [Articolo in rivista] Open Access
Cojutti P.G.; Lazzarotto D.; Candoni A.; Dubbini M.V.; Zannier M.E.; Fanin R.; Pea F., Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2020, 75, pp. 3029 - 3037 [Articolo in rivista] Open Access
Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, pp. 1 - 18 [Articolo in rivista]
Pea F., Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations, «JOURNAL OF INFECTION AND CHEMOTHERAPY», 2020, 26, pp. 900 - 907 [Articolo in rivista]
Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A., Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2020, 8, pp. 1 - 3 [Articolo in rivista] Open Access
Soriano A.; Rossolini G.M.; Pea F., The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs), «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2020, 18, pp. 415 - 422 [Articolo in rivista] Open Access
Sartore-Bianchi A.; Lonardi S.; Martino C.; Fenocchio E.; Tosi F.; Ghezzi S.; Leone F.; Bergamo F.; Zagonel V.; Ciardiello F.; Ardizzoni A.; Amatu A.; Bencardino K.; Valtorta E.; Grassi E.; Torri V.; Bonoldi E.; Sapino A.; Vanzulli A.; Regge D.; Cappello G.; Bardelli A.; Trusolino L.; Marsoni S.; Siena S., Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, «ESMO OPEN», 2020, 5, pp. 1 - 8 [Articolo in rivista] Open Access
Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A., Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience, «LUNG CANCER», 2020, 149, pp. 5 - 9 [Articolo in rivista]
Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A., New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [Articolo in rivista] Open Access
Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [Articolo in rivista] Open Access
Brandes A.A.; Ardizzoni A.; Artioli F.; Cappuzzo F.; Cavanna L.; Frassineti G.L.; Frassoldati A.; Leonardi F.; Longo G.; Maestri A.; Tassinari D.; Franceschi E.; Nunno V.D.; Pinto C., Fighting cancer in coronavirus disease era: Organization of work in medical oncology departments in Emilia Romagna region of Italy, «FUTURE ONCOLOGY», 2020, 16, pp. 1433 - 1439 [Articolo in rivista] Open Access
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [Articolo in rivista]
Dall'Olio F.G.; Maggio I.; Massucci M.; Mollica V.; Fragomeno B.; Ardizzoni A., ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data, «LUNG CANCER», 2020, 145, pp. 95 - 104 [Articolo in rivista]
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), «BRITISH JOURNAL OF CANCER», 2020, 123, pp. 26 - 32 [Articolo in rivista] Open Access
Ponce Aix S.; Talbot D.; Govindan R.; Dols M.C.; Postmus P.E.; Lewanski C.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Ong T.J.; Morgensztern D., Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 749 - 762 [Articolo in rivista]
Facchinetti F.; Mazzaschi G.; Barbieri F.; Passiglia F.; Mazzoni F.; Berardi R.; Proto C.; Cecere F.L.; Pilotto S.; Scotti V.; Rossi S.; Del Conte A.; Vita E.; Bennati C.; Ardizzoni A.; Cerea G.; Migliorino M.R.; Sala E.; Camerini A.; Bearz A.; De Carlo E.; Zanelli F.; Guaitoli G.; Garassino M.C.; Ciccone L.P.; Sartori G.; Toschi L.; Dall'Olio F.G.; Landi L.; Pizzutilo E.G.; Bartoli G.; Baldessari C.; Novello S.; Bria E.; Cortinovis D.L.; Rossi G.; Rossi A.; Banna G.L.; Camisa R.; Di Maio M.; Tiseo M., First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status, «EUROPEAN JOURNAL OF CANCER», 2020, 130, pp. 155 - 167 [Articolo in rivista]
Marfella, R; Paolisso, P; Sardu, C; Bergamaschi, L; D'Angelo, EC; Barbieri, M; Rizzo, MR; Messina, V; Maggi, P; Coppola, N; Pizzi, C; Biffi, M; Viale, P; Galie, N; Paolisso, G, Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients, «DIABETES & METABOLISM», 2020, 46, pp. 403 - 405 [Articolo in rivista]
Cavazzoni A.; Digiacomo G.; Alfieri R.; La Monica S.; Fumarola C.; Galetti M.; Bonelli M.; Cretella D.; Barili V.; Zecca A.; Giovannetti E.; Fiorentino M.; Tiseo M.; Petronini P.G.; Ardizzoni A., Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, «CANCERS», 2020, 12, pp. 1 - 16 [Articolo in rivista] Open Access
Felip E.; Ardizzoni A.; Ciuleanu T.; Cobo M.; Laktionov K.; Szilasi M.; Califano R.; Carcereny E.; Griffiths R.; Paz-Ares L.; Duchnowska R.; Garcia M.A.; Isla D.; Jassem J.; Appel W.; Milanowski J.; Van Meerbeeck J.P.; Wolf J.; Li A.; Acevedo A.; Popat S., CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations, «EUROPEAN JOURNAL OF CANCER», 2020, 127, pp. 160 - 172 [Articolo in rivista] Open Access
Di Nunno V.; Santoni M.; Mollica V.; Conti A.; Montironi R.; Battelli N.; Ardizzoni A.; Massari F., Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 211 - 226 [Articolo in rivista]